GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (OTCPK:RDPTF) » Definitions » EV-to-Revenue

Radiopharm Theranostics (Radiopharm Theranostics) EV-to-Revenue : (As of May. 25, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Radiopharm Theranostics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Radiopharm Theranostics's enterprise value is $8.87 Mil. Radiopharm Theranostics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, Radiopharm Theranostics's EV-to-Revenue for today is .

The historical rank and industry rank for Radiopharm Theranostics's EV-to-Revenue or its related term are showing as below:

RDPTF' s EV-to-Revenue Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0
Current: 50.27

RDPTF's EV-to-Revenue is ranked worse than
77.36% of 1038 companies
in the Biotechnology industry
Industry Median: 8.22 vs RDPTF: 50.27

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-25), Radiopharm Theranostics's stock price is $0.0008. Radiopharm Theranostics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00. Therefore, Radiopharm Theranostics's PS Ratio for today is .


Radiopharm Theranostics EV-to-Revenue Historical Data

The historical data trend for Radiopharm Theranostics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radiopharm Theranostics EV-to-Revenue Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23
EV-to-Revenue
- 129.00

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-Revenue - - - - -

Competitive Comparison of Radiopharm Theranostics's EV-to-Revenue

For the Biotechnology subindustry, Radiopharm Theranostics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Radiopharm Theranostics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Radiopharm Theranostics's EV-to-Revenue falls into.



Radiopharm Theranostics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Radiopharm Theranostics's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=8.865/0
=

Radiopharm Theranostics's current Enterprise Value is $8.87 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Radiopharm Theranostics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Radiopharm Theranostics  (OTCPK:RDPTF) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Radiopharm Theranostics's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.0008/0
=

Radiopharm Theranostics's share price for today is $0.0008.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Radiopharm Theranostics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Radiopharm Theranostics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Radiopharm Theranostics (Radiopharm Theranostics) Business Description

Traded in Other Exchanges
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is a Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialisation of health technologies.

Radiopharm Theranostics (Radiopharm Theranostics) Headlines

From GuruFocus

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 07-10-2022

PIVALATE ACHIEVES POSITIVE PHASE 2 DATA IN BRAIN METS TRIAL

By PRNewswire PRNewswire 10-19-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 06-30-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 06-20-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 06-10-2022